Gilead: A Decade-Best Quarter, and the Bill for Biktarvy Arrives Early

The quarter Gilead just printed is, by its own CEO's framing, the best commercial quarter the company has had in over ten years. And yet the single most consequential number on the call was not a sales figure at all. It was $2,600 — the per-30-day-supply price CMS has set for Biktarvy under the IRA's maximum fair price process, roughly a 38% discount to list in the Medicare channel, and the anchor for an expected $1.5 billion net hit to Biktarvy revenue in 2028.

What Actually Changed: Engagement Became a Number

For five straight quarters, drug pricing was a question Gilead answered with diplomacy. When asked about MFN and Medicaid exposure in August 2025, Dan O'Day leaned on structural insulation: “we have very limited patent exposure until the end of 2033 with a very strong clinical development plan” — Daniel P. O'Day, Chairman and Chief Executive Officer · 2025-08-07. By the Q3 2025 call, the language had softened into process: “we continue to have really ongoing good constructive engagements with the administration” — Daniel O'Day, Chairman and Chief Executive Officer · 2025-10-30. Both statements remain true. Neither is a number.

This quarter is a number, and the tone changes with it. O'Day does not merely disclose the IRA impact; he litigates it on the record: “the price set by CMS does not reflect the value of Biktarvy. It's a medicine that has transformed HIV treatment” — Daniel P. O’Day, Chairman and Chief Executive Officer · 2026-10-29 — before calling it a pill penalty that "discourages investment in these medicines." That is a materially more adversarial posture than anything in the prior five transcripts, and it is the freshest signal on the tape.

Based on our preliminary analysis, we currently expect full year 2028 Biktarvy revenue to decline from 2027... we expect a total net impact to Biktarvy revenue of approximately $1.5 billion in 2028, reflecting the lower price in Medicare in addition to related impacts across other US channels, including Medicaid, 340B, and other payer segments.

The net impact framing matters. As Johanna Mercier made clear under questioning, the company is deliberately not itemizing Medicare versus the spillover: “it's primarily Medicare. And then you have the spillover effect... the 1.5 is all encompassing” — Johanna Mercier, Chief Commercial & Corporate Affairs Officer · 2026-10-29. Crucially, it is also net of the Part D redesign drag rolling off — the $1.1 billion 2025 headwind that disappears in 2028 — which is why management can still promise both total product sales and EPS grow in 2028 versus 2027.

The Quality of a Decade-Best Number

The headline engine is real: base business sales of $8.2 billion rose 16% year-over-year, which Mercier flagged as “the highest year-over-year growth for our base business since 2015” — Johanna Mercier, Chief Commercial & Corporate Affairs Officer · 2026-10-29. HIV grew 18% to $6.2 billion, Biktarvy hit an all-time-high 53% US treatment share, Descovy rose 49%, Yeztugo contributed $305 million and is tracking to roughly $1 billion for the year, Livdelzi nearly doubled, and Trodelvy grew 42% to a ~$2 billion run rate.

But the composition deserves skepticism the sell-side largely skipped. HIV growth leaned on favorable inventory dynamics and a channel-mix-driven realized price benefit — the same two levers Mercier has flagged in prior quarters — and she pre-emptively warned that “the typical seasonal Q4 inventory that plays out in Q4 usually might be a little softer than usual” — Johanna Mercier, Chief Commercial & Corporate Affairs Officer · 2026-10-29. In other words, part of the "strongest decade" print is timing, not run-rate. Meanwhile cell therapy fell 18% and remains guided to decline mid-teens for the year.

The underlying P&L is genuinely strong: product gross margin of 88%, up from 86% on the November 2025 TAF royalty expiry, and a 50% quarterly operating margin. Free cash flow was robust even as GAAP optics looked terrible — a $10.5 billion net loss and a negative operating income are the arithmetic of roughly $12.9 billion of acquired IPR&D, including $1.4 billion of Q4 upfronts for the oral IL-23R program and the Vir collaboration. Strip that out and management points to EPS of $8.75–$9.10.

The cost of the deal spree is visible in the balance sheet: effective net cash of -$25.5 billion, with buybacks decelerating to $355 million in the latest reported quarter from over $700 million a year earlier. R&D ran near 23% of revenue in the last filed quarter — and it grew 19% year-over-year in Q3, with guidance now for a mid-to-high single-digit dollar increase for the full year.

The Next Act: Inflammation, and Two Holds Nobody Planned

The most distinctly new thing on this call is the elevation of inflammatory bowel disease from pipeline footnote to strategic pillar. Gilead now claims 13 clinical inflammation programs, a Phase 3 path for emvistagrast in ulcerative colitis in 2027, and an agreed acquisition of an oral IL-23 receptor inhibitor to pair with it. The vision is an oral backbone — “we are exploring its potential as an oral backbone for combination regimens designed to break through the efficacy ceiling seen with approved monotherapies” — Dietmar P. Berger, Chief Medical Officer · 2026-10-29. Note that this is the third consecutive quarter in which management has promised to "diversify" away from a franchise that is still ~70% of sales; Louise Chen asked the question again, and got the same answer as Geoff Meacham did in August. That recurrence is itself the tell: the mix shift is directionally real but slow.

The offsetting development is a clinical hold — actually two. PALISADES-1 and -2 for Kite-753 are on partial hold pending investigation of Grade 3/4 ICANS in a small number of patients, and 3107, the monthly oral pro-drug, remains held over unexpected metabolites. Cindy Perettie was careful to bound the first: “there's no patient death. There's no Grade 5” — Cindy Perettie, Executive Vice President · 2026-10-29. Both matter because anito-cel's December 23 PDUFA is the near-term catalyst the stock has been paid for, and Kite's next-generation franchise is the growth story after it.

The Tape Already Voted

Gilead's shares are up 32% in the last 90 trading days in one uninterrupted ascent, ahead of a report that delivered both the raise and the policy bill. At roughly 5.1x price-to-revenue, the market is paying for the 2028 growth promise rather than the 2026 beat. What went conspicuously quiet is telling: the IQVIA script-tracking debate, white bagging, the J-code and persistency rates — staples of the last four calls — did not surface once. Yeztugo's launch is no longer a controversy, it is a $1 billion line item. The controversy has moved to Washington, and for the first time Gilead has put a dollar figure on it.